LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

170.97 4.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

163.3

Max

171.05

Belangrijke statistieken

By Trading Economics

Inkomsten

1B

1.4B

Verkoop

264M

4.4B

K/W

Sectorgemiddelde

21.266

110.024

Winstmarge

31.187

Werknemers

93,000

EBITDA

266M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+38.51% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11B

28B

Vorige openingsprijs

166.95

Vorige sluitingsprijs

170.97

Nieuwssentiment

By Acuity

41%

59%

138 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 feb 2026, 22:31 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Winsten

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Winsten

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Winsten

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Marktinformatie

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Marktinformatie
Winsten

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Marktinformatie

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Winsten

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Marktinformatie

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Winsten

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Winsten

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Winsten

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Marktinformatie

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Winsten

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Winsten

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Winsten

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

38.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 231.23 USD  38.51%

Hoogste 266 USD

Laagste 174 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

12

Buy

4

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

138 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat